Sign in

CIK 0000906709

  • Non-accelerated filer
  • Smaller reporting company

NEKTAR THERAPEUTICS

Sign in to watch
Ticker
NKTR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
943134940
Phone
+1 415-482-5300
Business address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
Former names
INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
  1. 4 Grant or award Director acquired 11,700 shares (grant or award)
  2. 4 Grant or award Chief R&D Officer acquired 40,150 shares (grant or award)
  3. 4 Grant or award SVP & Chief Accounting Officer acquired 14,900 shares (grant or award)
  4. 4 Grant or award President & CEO acquired 94,100 shares (grant or award)
  5. 4 Grant or award SVP, COO & CFO acquired 40,150 shares (grant or award)
  6. 3 Insider Initial Statement of Ownership
  7. 4 Grant or award SVP & Chief Commercial Officer acquired 200,000 shares (grant or award)
  8. 3 Insider Initial Statement of Ownership
  9. 4 Open-market sale Chief R&D Officer sold 3,960 shares at $17.97 ($71,161)
  10. 4 Open-market sale SVP & Chief Accounting Officer sold 2,713 shares at $17.97 ($48,753)
  11. 4 Open-market sale President & CEO sold 13,556 shares at $17.97 ($243,601)
  12. 4 Open-market sale SVP, COO & CFO sold 8,863 shares at $17.97 ($159,268)
  13. 4 Open-market sale SVP, COO & CFO sold 25,000 shares at $19.79 ($494,750)
  14. 4 Open-market sale President & CEO sold 100,000 shares at an average $17.37 ($1,737,090)
  15. 4 Open-market sale SVP, COO & CFO sold 25,000 shares at $15.83 ($395,750)
  16. 4 Open-market sale Director sold 3,000 shares at $17.84 ($53,520)
  17. 4 Grant or award Chief R&D Officer acquired 75,000 shares (grant or award)
  18. 4 Grant or award SVP, COO & CFO acquired 75,000 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Open-market sale Director sold 2,375 shares at $18.06 ($42,893)

Page 13 of 49 · 970 filings